Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: An NRG Oncology/GOG study

OBJECTIVES: Predictive factors for efficacy of bevacizumab in advanced ovarian cancer have remained elusive. We investigated ascites both as a prognostic factor and as a predictor of efficacy for bevacizumab. METHODS: Using data from GOG 0218, patients receiving cytotoxic therapy plus concurrent and...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Gynecol Oncol
Main Authors: Ferriss, James S, Java, James J, Bookman, Michael A, Fleming, Gini F, Monk, Bradley J, Walker, Joan L, Homesley, Howard D, Fowler, Jeffrey, Greer, Benjamin E, Boente, Matthew P, Burger, Robert A
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4600605/
https://ncbi.nlm.nih.gov/pubmed/26216729
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2015.07.103
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados